R1	AND Arg1:T4 Arg2:T2	
R2	Has_qualifier Arg1:T2 Arg2:T3	
*	OR T1 T4
R3	Has_temporal Arg1:T1 Arg2:T5	
*	OR T7 T8
R4	Has_value Arg1:T10 Arg2:T11	
*	OR T9 T10
R5	Has_value Arg1:T13 Arg2:T14	
*	OR T15 T18 T17 T16 T19
R6	Subsumes Arg1:T12 Arg2:T15	
R7	AND Arg1:T12 Arg2:T13	
R8	AND Arg1:T21 Arg2:T22	
*	OR T28 T29 T30
*	OR T24 T25
R9	AND Arg1:T26 Arg2:T27	
R10	AND Arg1:T24 Arg2:T26	
R11	Subsumes Arg1:T24 Arg2:T28	
*	OR T34 T35
R12	AND Arg1:T37 Arg2:T34	
R13	Has_qualifier Arg1:T40 Arg2:T39	
*	OR T38 T40
R14	Subsumes Arg1:T37 Arg2:T38	
R15	Has_qualifier Arg1:T43 Arg2:T44	
R16	Has_qualifier Arg1:T45 Arg2:T46	
R17	Has_qualifier Arg1:T47 Arg2:T48	
R18	AND Arg1:T52 Arg2:T49	
R19	Has_negation Arg1:T52 Arg2:T51	
*	OR T50 T53 T54
R20	AND Arg1:T50 Arg2:T52	
R21	Has_qualifier Arg1:T56 Arg2:T57	
R22	Has_value Arg1:T58 Arg2:T59	
R23	Subsumes Arg1:T56 Arg2:T58	
R24	Has_qualifier Arg1:T62 Arg2:T63	
T1	Condition 0 19	Acute heart failure
T2	Condition 29 41	exacerbation
T3	Qualifier 23 28	acute
T4	Condition 45 66	chronic heart failure
T5	Temporal 67 90	within the past 2 weeks
T7	Procedure 103 136	cardiac resynchronization therapy
T8	Procedure 140 161	heart transplantation
T9	Condition 175 190	malignant tumor
T10	Person 194 209	life expectancy
T11	Value 210 225	under 12 months
T12	Drug 239 250	medications
T13	Measurement 267 283	thyroid function
T14	Value 260 266	affect
T15	Drug 285 289	L-T4
T16	Drug 291 302	carbimazole
T17	Drug 304 320	propylthiouracil
T18	Drug 322 332	amiodarone
T19	Drug 334 341	lithium
T21	Condition 345 354	Pregnancy
T22	Condition 359 375	lactation period
T23	Non-query-able 378 442	Participation in another clinical trial within the past 30 days.
T24	Condition 444 460	Contraindication
T25	Condition 464 475	intolerance
T26	Procedure 479 501	evidence-based therapy
T27	Condition 506 509	CHF
T28	Drug 519 531	beta-blocker
T29	Drug 533 572	angiotensin-converting enzyme inhibitor
T30	Drug 576 604	angiotensin receptor blocker
T34	Procedure 637 655	trial treatment(s)
T35	Drug 637 642;659 667	trial diluents
T37	Condition 613 629	hypersensitivity
T38	Drug 697 704	placebo
T39	Qualifier 708 713	other
T40	Drug 714 732	comparator drug(s)
T43	Condition 745 766	adrenal insufficiency
T44	Qualifier 735 744	Untreated
T45	Condition 779 802	pituitary insufficiency
T46	Qualifier 769 778	Untreated
T47	Condition 815 829	thyrotoxicosis
T48	Qualifier 805 814	Untreated
T49	Drug 847 860	levothyroxine
T50	Condition 900 927	acute myocardial infarction
T51	Negation 866 882	not be initiated
T52	Procedure 832 841	Treatment
T53	Condition 929 946	acute myocarditis
T54	Condition 951 968	acute pancarditis
T56	Condition 978 995	renal dysfunction
T57	Qualifier 971 977	Severe
T58	Measurement 997 1001	eGFR
T59	Value 1001 1018	=30 ml/min/1.73m2
T62	Condition 1034 1052	hepatic impairment
T63	Qualifier 1022 1033	Significant
T64	Measurement 1054 1063	Serum GPT
T65	Value 1064 1073	> 120 U/L
T66	Post-eligibility 1077 1199	Any disorder which, in the opinion of the investigator, might jeopardise subject's safety or compliance with the protocol.
